What is an appropriate replacement for Eliquis (apixaban) in a hospice patient?

Discontinue Eliquis in Hospice Patients

In hospice patients, Eliquis (apixaban) should generally be discontinued rather than replaced, as the goals of care shift from preventing future thromboembolic events to maximizing comfort and quality of life. The burden of continued anticoagulation—including bleeding risk, need for monitoring, and medication administration—typically outweighs any potential benefit in patients with limited life expectancy.

Rationale for Discontinuation

When patients transition to hospice care, the therapeutic goal fundamentally changes from disease prevention to symptom management and comfort. Research demonstrates that antithrombotic therapy is prescribed infrequently at hospice discharge (only 6.7% of patients), and when prescribed, often lacks documented clinical rationale 1. This reflects the clinical reality that:

• Bleeding risk increases while potential benefit from preventing future thrombotic events diminishes as life expectancy shortens
• Medication burden conflicts with hospice philosophy of comfort-focused care
• The pharmacodynamic effect of apixaban persists for at least 24 hours after the last dose (approximately two drug half-lives), meaning discontinuation does not create immediate thrombotic risk 2

When Replacement May Be Considered

In rare circumstances where anticoagulation continuation is deemed essential for symptom control (not prevention), consider these specific scenarios:

Active Symptomatic VTE

If the patient has current symptomatic deep vein thrombosis or pulmonary embolism causing distressing symptoms (pain, dyspnea, limb swelling):

• Low-dose subcutaneous unfractionated heparin (UFH) 5,000 IU every 8-12 hours is the most appropriate option 3
• UFH advantages in hospice setting:
  • Can be administered subcutaneously
  • Shorter half-life allows rapid discontinuation if bleeding occurs
  • Preferred in renal impairment (CrCl <30 mL/min) as liver is the main site of biotransformation 3
  • No monitoring required at prophylactic doses

Alternative: Low-Molecular-Weight Heparin

• Enoxaparin 40 mg subcutaneously once daily (prophylactic dosing) 3
• Simpler dosing than UFH but contraindicated if CrCl <30 mL/min 3
• More commonly used in hospice settings when prescribed (26% of antithrombotic prescriptions) 1

Important Caveats

Do NOT simply switch to another oral anticoagulant (rivaroxaban, dabigatran, warfarin). The evidence shows:

• Warfarin requires ongoing INR monitoring, which is burdensome and inconsistent with hospice goals
• Other DOACs have similar bleeding risks without offering advantages in the hospice setting
• Aspirin (most frequently prescribed at 57.1% when antithrombotics are given) 1 may be considered only for symptomatic relief in specific cardiovascular conditions, not as a replacement for therapeutic anticoagulation

Avoid continuation without clear symptom-based indication. Research shows that among hospice patients receiving antithrombotic therapy, 54.5% had no documented rationale for continuation 1. This represents potentially inappropriate prescribing that increases harm without benefit.

Clinical Decision Algorithm

1. Assess current symptoms: Is the patient experiencing distressing symptoms directly attributable to thrombosis (pain, severe dyspnea, limb swelling)?

   • No → Discontinue Eliquis, no replacement needed
   • Yes → Proceed to step 2

2. Evaluate renal function and bleeding risk:

   • CrCl ≥30 mL/min, low bleeding risk → Consider enoxaparin 40 mg SC daily
   • CrCl <30 mL/min or moderate-high bleeding risk → Consider UFH 5,000 IU SC every 8-12 hours
   • High bleeding risk with minimal symptoms → Discontinue, focus on comfort measures

3. Reassess regularly: If symptoms resolve or patient's condition deteriorates, discontinue anticoagulation

Common Pitfalls to Avoid

• Do not bridge with therapeutic-dose anticoagulation when discontinuing Eliquis in hospice patients
• Do not use prothrombin complex concentrates (PCC) or andexanet alfa 4, 5 unless the patient has life-threatening bleeding requiring emergent reversal—these are not indicated for routine discontinuation
• Do not continue anticoagulation "just in case" without specific symptom-based indication
• Remember that apixaban's effect persists 24 hours after the last dose 2, so there is no urgent need for immediate replacement

The overarching principle: In hospice care, medication decisions should prioritize quality of life and symptom management over prevention of future events. Discontinuation of Eliquis without replacement aligns with this goal in the vast majority of patients.